TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
19.795
-0.005 (-0.03%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close19.800
Open19.770
Bid0.000 x 0
Ask0.000 x 0
Day's Range19.650 - 19.890
52 Week Range18.930 - 31.290
Volume1,519,024
Avg. Volume748,596
Market Cap31.159B
Beta (3Y Monthly)0.46
PE Ratio (TTM)28.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.81 (4.06%)
Ex-Dividend Date2018-03-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Revenue Projections for Endo International for 2018
    Market Realist2 hours ago

    Revenue Projections for Endo International for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).

  • Reuters4 hours ago

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.

  • Reuters4 hours ago

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.

  • Reuters14 hours ago

    Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.

  • Reuters14 hours ago

    Takeda sets vote date, aims to close $62 billion Shire deal on January 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion (47.92 billion pounds) acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.

  • Financial Times15 hours ago

    [$$] Takeda sets date for shareholder vote on £46bn Shire deal

    The key vote comes as a group of shareholders, including several founding family members of Takeda, steps up a campaign to derail a deal that Japan’s largest drugmaker sees as critical to catapulting itself into the ranks of the world’s biggest pharmaceutical companies. “With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,” Christophe Weber, the chief executive of Takeda, said in a statement. Takeda, which initially said it would hold the vote in early 2019, has brought the date forward as management has become increasingly confident about the prospects of the company securing a two-thirds approval from shareholders to issue new shares to finance the acquisition.

  • Financial Times18 hours ago

    [$$] Takeda/Japan activism: importunate imports

    Japanese companies sometimes use imports as performance enhancers. One of these, Takeda boss Christophe Weber, now finds himself at odds with another — investor activism. The Frenchman must believe he ...

  • Financial Times18 hours ago

    [$$] Takeda and Shire to pay almost $1bn in deal fees and expenses

    Lawyers will take home more than $105m combined, accountants will make about $26m and public relations advisers will earn almost $10m. One person close to the company said the figure covered matters relating to the future company, such as the listing of new Takeda shares in the US and the winding up of Shire shares that are listed there.

  • Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources
    Reuters3 days ago

    Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

    Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday. Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio. Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.

  • Reuters3 days ago

    Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

    Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday. Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio. Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.

  • Moody's4 days ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade

    Moody's Japan K.K. has assigned A2 ratings to Takeda Pharmaceutical Company Limited's (A2 review for downgrade) proposed senior unsecured notes. These new notes are under review for downgrade as are Takeda's ...

  • Takeda Hires Banks for Euro Bonds to Finance Shire Takeover
    Bloomberg4 days ago

    Takeda Hires Banks for Euro Bonds to Finance Shire Takeover

    (Bloomberg) -- Takeda Pharmaceutical Co. Ltd has picked banks to arrange a euro bond offering to finance its $62 billion acquisition of larger rival Shire Plc.

  • Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript

    NKTR earnings call for the period ending September 30, 2018.

  • Takeda CEO confident of investor backing for $62 billion Shire deal
    Reuters7 days ago

    Takeda CEO confident of investor backing for $62 billion Shire deal

    The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire (SHP.L), despite some shareholders' fears about the resulting debt burden. Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move. "We are quite satisfied with our current progress at Takeda.

  • Reuters7 days ago

    Takeda CEO confident of investor backing for $62 billion Shire deal

    The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire, despite some shareholders' fears about the resulting debt burden. Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move. "We are quite satisfied with our current progress at Takeda.

  • The Wall Street Journal11 days ago

    [$$] Shire 3Q Net Profit Falls on Taxes

    Shire said that net profit fell 2.5% in the third quarter on higher tax expenses as well as reorganization costs.

  • Takeda hikes annual profit forecast by a third after second-quarter profit jump
    Reuters12 days ago

    Takeda hikes annual profit forecast by a third after second-quarter profit jump

    Japan's Takeda Pharmaceutical Co Ltd on Wednesday boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma. It now expects to post 268.9 billion yen ($2.4 billion) in operating profit for the year ending in March, beating an average Refinitiv estimate of 222.7 billion yen from eight analysts. Takeda is working to close a $62 billion acquisition of London-listed Shire.

  • Financial Times13 days ago

    [$$] Takeda raises forecast on cancer drug outlook

    Takeda has raised its annual net profit forecast by 36 per cent on the back of cost cuts and an improved outlook for its blockbuster cancer drug Velcade. The upgrade came as Japan’s largest drugmaker seeks to close its £46bn takeover of Irish drugmaker Shire in a bid to strengthen its pipeline and catapult the company into the ranks of the world’s biggest pharmaceutical companies. Takeda said it now expects a net profit of ¥189.5bn ($1.7bn) compared to its earlier profit forecast of ¥139bn for the fiscal year ending in March 2019 while it raised its revenue outlook by 0.7 per cent to ¥1.75tn.

  • Reuters15 days ago

    UK Stocks-Factors to watch on Oct 29

    (Adds futures, company news item) Oct 29 - Britain's FTSE 100 index is seen opening 10 points higher at 6,949 on Monday, according to financial bookmakers, with FTSE 100 futures up 0.87 percent ahead of ...

  • Reuters15 days ago

    Takeda proposes sale of Shire drug to gain European approval

    The Japanese drug developer said it had proposed divesting Shire's pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights. It said it did not expect the issue to delay its closing of the takeover of Shire and was the only issue it was discussing with European Union regulators after receiving approvals in China and Japan for the deal.

  • Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
    Zacks17 days ago

    Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark

    Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.

  • A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga
    Market Realist17 days ago

    A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

    Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter compared to $512.0 million in the third quarter of 2017, reflecting a ~37.7% YoY (year-over-year) rise.

  • Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool18 days ago

    Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript

    SGEN earnings call for the period ending September 30, 2018.

  • Reuters26 days ago

    Takeda gets Japanese approval for $62 billion Shire purchase

    "Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,”Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulators.

  • Takeda gets Japanese approval for $62 billion Shire purchase
    Reuters26 days ago

    Takeda gets Japanese approval for $62 billion Shire purchase

    "Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,” Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulators.